First Business Financial Services Inc. Trims Holdings in Pfizer Inc. (NYSE:PFE)

Share on StockTwits

First Business Financial Services Inc. trimmed its position in Pfizer Inc. (NYSE:PFE) by 10.0% during the third quarter, Holdings Channel.com reports. The firm owned 7,496 shares of the biopharmaceutical company’s stock after selling 834 shares during the period. First Business Financial Services Inc.’s holdings in Pfizer were worth $269,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in PFE. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Pfizer by 3.0% during the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 107,965 shares of the biopharmaceutical company’s stock worth $3,879,000 after acquiring an additional 3,189 shares during the period. Hayek Kallen Investment Management lifted its holdings in shares of Pfizer by 1.2% during the 3rd quarter. Hayek Kallen Investment Management now owns 98,437 shares of the biopharmaceutical company’s stock worth $3,537,000 after acquiring an additional 1,179 shares during the period. Whitnell & Co. lifted its holdings in shares of Pfizer by 390.0% during the 3rd quarter. Whitnell & Co. now owns 50,507 shares of the biopharmaceutical company’s stock worth $1,815,000 after acquiring an additional 40,200 shares during the period. Carillon Tower Advisers Inc. lifted its holdings in shares of Pfizer by 54.3% during the 3rd quarter. Carillon Tower Advisers Inc. now owns 578,069 shares of the biopharmaceutical company’s stock worth $20,770,000 after acquiring an additional 203,400 shares during the period. Finally, DT Investment Partners LLC lifted its holdings in shares of Pfizer by 9.1% during the 3rd quarter. DT Investment Partners LLC now owns 121,907 shares of the biopharmaceutical company’s stock worth $4,381,000 after acquiring an additional 10,128 shares during the period. Institutional investors own 71.52% of the company’s stock.

PFE traded up $0.14 on Friday, reaching $37.05. 24,924,227 shares of the company’s stock were exchanged, compared to its average volume of 23,366,957. The company’s 50 day moving average is $36.62 and its 200-day moving average is $39.26. The company has a market cap of $207.30 billion, a price-to-earnings ratio of 12.35, a PEG ratio of 2.11 and a beta of 0.67. Pfizer Inc. has a twelve month low of $33.97 and a twelve month high of $46.47. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.21 and a current ratio of 1.47.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.13. Pfizer had a net margin of 30.57% and a return on equity of 28.61%. The firm had revenue of $12.68 billion during the quarter, compared to the consensus estimate of $12.37 billion. During the same quarter in the prior year, the company earned $0.78 EPS. The company’s revenue was down 4.6% on a year-over-year basis. Sell-side analysts forecast that Pfizer Inc. will post 2.96 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a $0.36 dividend. This represents a $1.44 annualized dividend and a yield of 3.89%. The ex-dividend date of this dividend is Thursday, November 7th. Pfizer’s dividend payout ratio (DPR) is 48.00%.

In other news, major shareholder Pfizer Inc acquired 50,000 shares of the stock in a transaction on Tuesday, September 17th. The stock was bought at an average price of $18.00 per share, with a total value of $900,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Scott Gottlieb acquired 3,000 shares of the stock in a transaction on Friday, August 23rd. The stock was purchased at an average cost of $34.72 per share, with a total value of $104,160.00. Following the transaction, the director now directly owns 3,000 shares of the company’s stock, valued at $104,160. The disclosure for this purchase can be found here. 0.09% of the stock is owned by company insiders.

A number of analysts recently issued reports on the stock. UBS Group reissued a “neutral” rating and set a $43.00 target price on shares of Pfizer in a research report on Monday, August 5th. ValuEngine raised shares of Pfizer from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Bank of America assumed coverage on shares of Pfizer in a research report on Wednesday, October 16th. They set a “neutral” rating and a $37.00 target price for the company. DZ Bank raised shares of Pfizer from a “sell” rating to a “hold” rating and set a $36.00 target price for the company in a research report on Wednesday, August 28th. Finally, Credit Suisse Group reissued a “hold” rating and set a $41.30 target price on shares of Pfizer in a research report on Wednesday. Nine investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $44.02.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Read More: Oversold

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.